Table of Contents Table of Contents
Previous Page  674 / 812 Next Page
Information
Show Menu
Previous Page 674 / 812 Next Page
Page Background

S670

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1004

Treating ADHD in people with

intellectual disabilities

K. Courtenay

UCL, Department Mental Health Sciences, London, United Kingdom

Objectives

Attention Deficit Hyperactivity Disorder (ADHD) is

more prevalent in people with intellectual disabilities (ID). Drug

therapy is the primary treatment for ADHD targeting the core signs

of inattention, impulsivity, and hyperactivity (NICE 2013). Knowl-

edge on ADHD has been gleaned from studies in children and

childrenwith ID. Peoplewith ID have comorbid disorders for exam-

ple, autism and epilepsy that can complicate the management of

ADHD. Knowledge of the effects of treatment is essential in manag-

ingADHD inpeoplewith ID. The current evidence on the application

of drug therapy for ADHD in ID is described.

Method

A literature review of publications in English language

was undertaken.

Results

Using medication to treat ADHD is effective in treat-

ing the signs of ADHD in people with ID. The response rates in

ID to drug therapy for ADHD approximates to 55% that is lower

than in the general population. People with ID experience more

side effects from medication that can lead to withdrawal from

treatment. Guidelines exist internationally on the appropriate pre-

scribing of medication. Methylphenidate, a psycho-stimulant drug

is the drug of first choice. Atomxetine, a non-stimulant drug, is

effective in people with ID.

Conclusions

ADHD in people with ID is treatable but clinicians

need to be knowledgeable and skilled in managing the disorder

in people with ID. Newer drugs could offer more because of their

different profile of more tolerable side effects.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1989

EV1005

Analysis of the diagnoses of patients

treated with palmitate paliperidone

C. Diago Labrador

, A.M

. Álvarez Montoya , T. Ruano Hernández

Clínica privada, Clínica privada, Algeciras, Spain

Corresponding author.

Objectives

Review of the diagnoses of the treated patients with

palmitate paliperidone for one year in a mental health unit, as well

as some of their key sociodemographic characteristics, the length

of the hospital stay and the average treatment according to clinical

diagnosis.

Methods

Descriptive epidemiological study including patients

admitted to our hospital. It covers the period from January 2014

to December 2014.

Results

For the period between January and December, a total of

315 patients were admitted in our mental health hospital unit, of

which 45 were treated with paliperidone palmitate. The diagnosis

were: schizophrenia (25 patients; 55.56%), schizoaffective disorder

(7 patients; 15.56%), delusional disorder (5 patients; 11.11%), bipo-

lar disorder (1 patient; 2.22%), personality disorder (2 patients;

4.44%), obsessive-compulsive disorder (1 patient; 2.22%), organic

brain disorder (1 patient; 2.22%), schizophreniform disorder (1

patient; 2.22%) andmental retardation (1 patient; 2.22%). Themean

age of patients was 35.7 years old. The most common marital sta-

tus was unmarried state (30 patients; 66.6%). The average stay per

hospital admission was 19.33 days. The most abused drugs were

tobacco (31 patients; 68.8%). Themean dose of paliperidone palmi-

tate was 137.5mg. Schizophrenic patients need higher doses of

treatment.

Conclusions

A significant improvement in functionality was

observed in our patients. What’s proven efficacy and good

tolerability and adherence, so we consider paliperidone palmitate

as a drug of first choice in the treatment of schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1990

EV1006

Nalmefene and alcohol use disorder

M.D. Díaz Pi˜neiro

, M.A

. Gutiérrez Ortega ,

M. Mateos Agut , E. Martín Martínez , B. Sanz Cid

University Hospital of Burgos, Psychiatry, Burgos, Spain

Corresponding author.

Introduction

Psychopharmacology study.

Objective

To evaluate Nalmefene effectiveness in clinical practice

in patients diagnosed with alcohol use disorder.

Method

Descriptive, prospective and observational study with

patients diagnosed with alcohol use disorder, treated with Nalme-

fene during 6 months.

Results

Twenty-seven patients (9 women and 18 men); average

age: 47.92. A total of 64.28% with F10 as an exclusive main diagno-

sis. Drink urge perception at the beginning: 6.37 points over 10.6

months later, 3.25 points. Loss of alcohol drinking control percep-

tion at the beginning: 6.03 points over 10. Six months later, it is

reduced down to 2.37 points. GGT reduction (from 107.18 to 36.5

U.I./L) and Mean Corpuscular Volume reduction (from 90.2 to 88.9

fl). The average of days/month with binge drinking at the begin-

ning was 16.18 SD (standard drinks); and monthly total of alcohol

consumption is 182.75 SD. After a month: 4.6 days and 66.52 SD.

After 6 months, it decreases to 4 days/month and 63.3 SD. The

results of the Rhode Island Change Assessment scale are: 7.4% in

pre-contemplation stage, 70.37% contemplation stage, 3.7% action

stage and 18.5% in maintenance stage. Six months later: 75% con-

templation, 12.5% action and 12.5% maintenance stage. The main

side effects were: nausea and vomiting, 22.22% at the beginning

and 12.5% that persist with intakes; sexual side effects in 22.22%

throughout the treatment; the 14.8% report increased sleeping and

dreaming, 14.8% report restlessness, after six months drowsiness

prevails with a 18%. At first, orthostatic dizziness appears in a 14.8%,

disappearing 4 weeks later.

Conclusion

Nalmefene is effective in reducing alcohol consump-

tion, with few side effects and good acceptance.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1991

EV1007

Antipsychotic polypharmacy at the

clinic of psychiatry, clinical centre of

Serbia

N. Divac

1 ,

, A. Damjanovic

2

, R. Stojanovic

1

, K. Savic Vujovic

1

,

B. Letunica

3

, M. Prostran

1

1

Faculty of Medicine, University of Belgrade, Department of

Pharmacology-Clinical Pharmacology and Toxicology, Belgrade,

Serbia

2

Clinical Centre of Serbia, Clinic of Psychiatry, Belgrade, Serbia

3

University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Corresponding author.

Introduction

Antipsychotic polypharmacy is not supported by

current guidelines. However, it is often present in practice. A com-

mon reason for this is to gain a greater, faster therapeutic response

and reduce the doses of individual drugs, thus reducing the adverse

effects.

Aims and Objectives

The aim of this study is to analyze the preva-

lence of antipsychotic polypharmacy at the Clinic of Psychiatry,